Format

Send to

Choose Destination
Eur Urol. 2015 Feb;67(2):191-4. doi: 10.1016/j.eururo.2014.07.008. Epub 2014 Aug 5.

Urinary melatonin levels, sleep disruption, and risk of prostate cancer in elderly men.

Author information

1
Centre of Public Health Sciences, University of Iceland, Reykjavik, Iceland; Faculty of Medicine, University of Iceland, Reykjavik, Iceland; The Icelandic Cancer Society, Reykjavik, Iceland.
2
Department of Epidemiology, Harvard School of Public Health, Boston, MA, USA. Electronic address: sec110@mail.harvard.edu.
3
Department of Epidemiology, Harvard School of Public Health, Boston, MA, USA; Channing Division of Network Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
4
Department of Biostatistics, Harvard School of Public Health, Boston, MA, USA.
5
Centre of Public Health Sciences, University of Iceland, Reykjavik, Iceland; Department of Epidemiology, Harvard School of Public Health, Boston, MA, USA; Clinical Epidemiology Unit, Örebro University and Örebro University Hospital, Örebro, Sweden.
6
Division of Sleep Medicine, Harvard Medical School, Boston, MA, USA; Division of Sleep and Circadian Disorders, Departments of Medicine and Neurology, Brigham and Women's Hospital, Boston, MA, USA.
7
Laboratory of Epidemiology and Population Sciences, National Institute on Aging, Bethesda, MD, USA.
8
Centre of Public Health Sciences, University of Iceland, Reykjavik, Iceland; Icelandic Heart Association, Kopavogur, Iceland.
9
Faculty of Medicine, University of Iceland, Reykjavik, Iceland; Icelandic Heart Association, Kopavogur, Iceland.
10
Centre of Public Health Sciences, University of Iceland, Reykjavik, Iceland; Faculty of Medicine, University of Iceland, Reykjavik, Iceland; Department of Epidemiology, Harvard School of Public Health, Boston, MA, USA.
11
Centre of Public Health Sciences, University of Iceland, Reykjavik, Iceland; Department of Epidemiology, Harvard School of Public Health, Boston, MA, USA; Channing Division of Network Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.

Abstract

Melatonin has anticarcinogenic properties in experimental models. We undertook a case-cohort study of 928 Icelandic men without prostate cancer (PCa) nested within the Age, Gene/Environment Susceptibility (AGES)-Reykjavik cohort to investigate the prospective association between first morning-void urinary 6-sulfatoxymelatonin (aMT6s) levels and the subsequent risk for PCa, under the hypothesis that men with lower aMT6s levels have an increased risk for advanced PCa. We used weighted Cox proportional hazards models to assess the association between first morning-void aMT6s levels and PCa risk, adjusting for potential confounders. A total of 111 men were diagnosed with incident PCa, including 24 with advanced disease. Men who reported sleep problems at baseline had lower morning aMT6s levels compared with those who reported no sleep problems. Men with morning aMT6s levels below the median had a fourfold statistically significant increased risk for advanced disease compared with men with levels above the median (hazard ratio: 4.04; 95% confidence interval, 1.26-12.98). These results require replication in larger prospective studies with longer follow-up.

PATIENT SUMMARY:

In this report, we evaluated the prospective association between urinary aMT6s levels and risk of PCa in an Icelandic population. We found that lower levels of aMT6s were associated with an increased risk for advanced PCa.

KEYWORDS:

Circadian rhythm; Melatonin levels; Prostate cancer

PMID:
25107635
PMCID:
PMC4318783
DOI:
10.1016/j.eururo.2014.07.008
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center